Rising Tide Lifts All CAR-T Ships After Gilead/Kite Deal, Kymriah Approval

Excitement around cell therapy has been building in recent years, but companies expect interest to accelerate after Gilead agreed to buy Kite for $11.9bn and Novartis won the first ever CAR-T approval.

boat anchored in a bay, luxury yacht

An outstanding week for chimeric antigen receptor T cell (CAR-T) therapy companies, between Gilead Sciences Inc.'s $11.9bn purchase of Kite Pharma Inc. and US FDA approval for Novartis AG's Kymriah (tisagenlecleucel), could turn into a great run for cell therapy developers.

Gilead's Kite acquisition showed that big pharma and large biotech companies see significant commercial value in CAR-T therapies – enough...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Strategy

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.